Pfizer Prevnar vaccine wins approval for ages 6-17

Sat Jan 26, 2013 3:41am IST

Related Topics

Stocks

   

(Reuters) - Pfizer Inc on Friday said U.S. regulators had approved wider use of its Prevnar 13 vaccine to prevent infections with pneumococcal bacteria, for children and adolescents aged 6 years to 17 years.

The product was already approved in the United States to prevent infections among children aged 6 weeks through 5 years. It is also approved for adults aged 50 and older.

The vaccine protects against infection with 13 strains of the Streptococcus pneumoniae bacterium. The bacterium can cause pneumonia, ear infections and other problems.

Prevnar 13 has annual sales of about $3.5 billion, making it Pfizer's third-biggest brand. It was approved in 2010, and has largely displaced an older vaccine called Prevnar, which protected against only 7 prevalent strains of the bacterium.

(Reporting by Ransdell Pierson; Editing by David Gregorio and Dan Grebler)

FILED UNDER:

Fighting Ebola

Reuters Showcase

IS Claim

IS Claim

Islamic State says beheads second Japanese hostage.  Full Article 

Ukraine Crisis

Ukraine Crisis

Death toll mounts in Ukraine fighting after peace talks fail.  Full Article 

Fifth Title

Fifth Title

Djokovic reigns supreme at Australian Open.  Full Article 

Journalist Freed

Journalist Freed

Jailed Al Jazeera journalist Peter Greste leaves Egypt for Australia.  Full Article 

Reuters Poll

Reuters Poll

RBI seen holding rates steady on Tuesday, minority of analysts expect cut.  Full Article 

Doubles Title

Doubles Title

Hingis wins Australian Open mixed doubles title with Paes.  Full Article 

Houston's Daughter

Houston's Daughter

Bobbi Kristina Brown revived after found unresponsive in tub  Full Article 

Supply Glut

Supply Glut

Sugar mills seek govt help to dispose of supply surplus.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage